メルクの第3四半期の利益は予想を上回ったが,同社は配当を上げ,投資家の関心が高まった. Merck's Q3 earnings missed estimates, but the company boosted its dividend and saw rising investor interest.

メルク・アンド・コーは,第3四半期の1株当たり1.94ドルの利益を報告し,2.08ドルの見積もりを下回ったが, 44.54%の資本収益率と 29.63%の純利益率で強い財務状態を維持した. Merck & Co. reported third-quarter earnings of $1.94 per share, slightly below the $2.08 estimate, while maintaining strong financial health with a 44.54% return on equity and 29.63% net margin. 同社は四半期配当を0.85ドルに上げ,3.2%の利回りをもたらし,ステーブルポイントパートナーズLLCとチャールズ・シュワブ投資管理を含む機関投資家が株を増やした. The company raised its quarterly dividend to $0.85, yielding 3.2%, and saw institutional investors increase their stakes, including Stablepoint Partners LLC and Charles Schwab Investment Management. メルクは,キートラダとガーダシルで知られており,市場キャピタルは2665億4千万ドルで,取引価格は107.39ドルで,合意の"ホールド"評価は114.20ドルの目標です. Merck, known for Keytruda and Gardasil, has a market cap of $266.54 billion, trades at $107.39, and holds a consensus "Hold" rating with a $114.20 target.